Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.73 USD | +4.37% | +3.65% | +85.94% |
03-25 | Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell | MT |
03-25 | Dyne Therapeutics, Inc. Announces Management Changes | CI |
Evolution of the average Target Price on Dyne Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Dyne Therapeutics, Inc.
Chardan Research | |
Stifel Nicolaus | |
Piper Sandler | |
Oppenheimer | |
HC Wainwright | |
Raymond James | |
Guggenheim | |
JPMorgan Chase |
EPS Revisions
- Stock Market
- Equities
- DYN Stock
- Consensus Dyne Therapeutics, Inc.